• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Anti-inflammatory drug may help prevent heart attacks
Conclusion This well-conducted study shows promising signs that canakinumab may reduce the risk of future heart attacks and other cardiovascular events in people who've had them in the past. But before any changes are made to the current licensing of this drug, further research is needed to confirm the beneficial effects and the optimal dose. Most importantly, researchers will need to focus on the observation that the drug lowered white blood cell counts and increased the risk of fatal infection. They estimated around 1 in every 300 people taking canakinumab would die of a fatal infection. This number, while low, is sti...
Source: NHS News Feed - August 30, 2017 Category: Consumer Health News Tags: Heart/lungs Source Type: news

Text alerts 'help prompt people to take their pills'
Conclusion This randomised study found a text messaging reminder service led to more people taking medication as prescribed. It appears this was because not taking the medication or not responding to the text led to a discussion with a healthcare professional, which influenced people to continue taking their medicines. The study was clearly reported and was of adequate size to find a difference between the two groups, if there was one. But, as with all studies, there are some limitations to consider. The results of the study may not be applicable to everyone. The recruitment process meant the participants were already ...
Source: NHS News Feed - December 8, 2014 Category: Consumer Health News Tags: Medical practice Medication Heart/lungs Source Type: news

Correlation between use of simvastatin and lovastatin and female lung cancer risk: a nationwide case-control study.
CONCLUSIONS: Simvastatin use at a DDD of more than 150 is correlated with an approximately 20% reduction in the risk of lung cancer in women. PMID: 25421876 [PubMed - as supplied by publisher]
Source: Clinical Lung Cancer - November 25, 2014 Category: Cancer & Oncology Authors: Yang TY, Lin WM, Lin CL, Sung FC, Kao CH Tags: Int J Clin Pract Source Type: research

Correlation between use of simvastatin and lovastatin and female lung cancer risk: a nationwide case–control study
ConclusionsSimvastatin use at a DDD of more than 150 is correlated with an approximately 20% reduction in the risk of lung cancer in women.
Source: International Journal of Clinical Practice - November 25, 2014 Category: Internal Medicine Authors: T.‐Y. Yang, W.‐M. Lin, C.‐L. Lin, F.‐C. Sung, C.‐H. Kao Tags: Original Paper Source Type: research